The Transformation Stratosphere

Healthcare has more data and intelligence than ever. The real challenge is recognizing what matters early enough to change what happens next.

Executive Summary

Healthcare organizations are investing heavily in AI, analytics, interoperability, and automation. Forrester expects U.S. healthcare providers to spend $69 billion on technology in 2026, up 7.6% year over year. 

But more technology does not automatically mean faster action.

Patient-flow issues, claims risks, utilization changes, and operational bottlenecks are often visible in the data before they become bigger problems. The challenge is recognizing those signals, understanding their impact, and responding while there is still time to change the outcome.

That gap between signal and action is decision latency and reducing it may be one of healthcare’s most important performance opportunities.

Healthcare has spent years improving visibility.

Executives can now monitor utilization, financial performance, patient volumes, claims, staffing, and dozens of other measures through increasingly sophisticated dashboards.

But a dashboard showing that a number has moved is still asking a human being to connect the rest of the dots.

Why did it move? Is the change temporary or significant? What else is affected? Does somebody need to respond? And if they do, what should they do next?

This is where healthcare analytics is beginning to evolve.

ISG's 2026 healthcare research points to organizations moving AI beyond isolated pilots and into clinical, administrative, and payer workflows. It also sees the market progressing from generating insights toward using intelligence to support workflow execution and orchestration.

That distinction matters.

A system that tells a care team, finance leader, or operations manager what happened yesterday is useful. A system that spots an emerging issue, explains why it matters, and helps trigger the right response while there is still time to influence the outcome is something different.

From More Data to Faster Action

This is also why the conversation about healthcare data needs to move beyond integration alone.

Connecting clinical, claims, diagnostic, financial, operational, and patient information is important. But connection is valuable because of what it allows an organization to do next.

That is the idea behind Altiaris for healthcare: our decision intelligence platform that brings signals from across the organization together, identifies emerging delays or risks, helps teams understand what requires attention, and moves the resulting decision into the appropriate workflow.

The broader opportunity is bigger than any one platform.

Healthcare organizations will continue to collect more data. They will continue to invest in AI. The organizations that gain the most from those investments may not be the ones with the most sophisticated dashboards or the largest number of models.

They may simply be the ones that become better at recognizing what matters sooner, deciding what to do, and acting while there is still time to make a difference.

Request an Altiaris Healthcare Demo

The most valuable manufacturing scenarios are often the hardest to capture in real-world data. A production line may run for months without a particular type of defect. A critical machine failure may happen only once in several years. An unusual combination of operating conditions may never occur during normal production. Relying on those events to generate enough data isn’t a practical way to build an AI strategy. 

That’s why synthetic data is gaining traction right now, giving manufacturers the ability to simulate rare events instead of waiting for them to happen.

This matters because manufacturing AI is moving beyond experimentation.

Deloitte's 2026 survey of more than 140 manufacturers found that 84% already report measurable value from AI, but only 20% of use cases have been scaled consistently across sites or enterprise-wide. The challenge has shifted from proving that AI can work to building the capabilities to scale it.

Data is becoming part of that scaling equation. Analysts predict that spending on AI data will rise from $826 million in 2025 to $3.1 billion in 2026, reflecting the growing need for data foundations as AI adoption accelerates. Gartner's research also identifies synthetic data's reliability and utility as an emerging consideration for enterprises.

Manufacturing presents a particularly difficult version of this challenge. The data AI needs most may come from events that are rare, unpredictable, or too costly to reproduce safely. Synthetic data changes the equation by allowing manufacturers to create those scenarios digitally and give AI more opportunities to learn from them.

However, synthetic data isn't a substitute for reality. The strongest approach combines simulated scenarios with real production data.

That's where the opportunity becomes tangible.

NVIDIA recently highlighted how Corning's optical-fiber manufacturing team used synthetic defect images alongside real data to train a visual-inspection model. The resulting model achieved near-perfect precision and recall in NVIDIA's benchmark.

The lesson isn't that manufacturers should start generating synthetic data for everything. It's that data scarcity can be addressed strategically.

To get there, you must start with the AI use cases where rare failures, defects, or abnormal conditions are holding back progress. Use simulation to create those scenarios, validate them against real production data, and feed the resulting insights back into the model-development cycle. Over time, synthetic and real-world data can become part of the same learning loop, with simulation expanding what AI can experience, while production data keeps it grounded in reality.

For manufacturers moving from AI pilots to scaled applications, that ability to create the right data could become a competitive capability in its own right. Synthetic data makes that possible, giving industrial AI a head start on the problems the real factory hasn't encountered yet.

If you can predict a potential machine failure, you should be able to fix it before it brings production to a halt. That’s the core promise of predictive maintenance, and it’s easy to see why it’s so attractive to manufacturers.

Data shows that the technology does deliver.Deloitte's 2026 research finds that manufacturers using predictive maintenance report 19% less unplanned downtime than those using preventive maintenance. Against reactive maintenance, the reduction rises to 53%.

But notice what those numbers don't say: zero downtime.

Because predicting a failure is only half the equation. AI can monitor equipment health, spot patterns, and flag potential faults. What actually determines whether that warning becomes avoided downtime is what happens next.

Leading organizations are starting to demonstrate what happens when prediction is connected to action.

BCG highlights one major European health system that embedded predictive, generative, and agentic AI into end-to-end clinical workflows. In its evidence-based care program, AI analyzes patient information, matches it against validated clinical pathways, and recommends the next best step. Once a clinician validates the pathway, the workflow can execute the required scheduling and follow-ups. The health system has reported a 10–20% increase in clinical capacity, alongside better patient adherence and more consistent care.

Here's the distinction that matters.

Predictive healthcare tells you what might happen. Preventive healthcare connects that insight to the people, pathways, resources, and actions needed to change what happens next.